Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Heteroclitic immunization induces tumor immunity.

Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolić-Zugić J.

J Exp Med. 1998 Nov 2;188(9):1553-61.

2.

Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.

Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ.

Cancer Res. 2000 Dec 15;60(24):6995-7001.

3.
4.

Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.

Gritzapis AD, Sotiriadou NN, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2004 Nov;53(11):1027-40. Epub 2004 May 26.

PMID:
15164233
5.

Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.

Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK.

Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.

PMID:
19169682
6.
8.

Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.

Kikuchi T, Uehara S, Ariga H, Tokunaga T, Kariyone A, Tamura T, Takatsu K.

Immunology. 2006 Jan;117(1):47-58.

9.

DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.

Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X, Ferrone S, Kozbor D.

Cancer Res. 2005 Apr 15;65(8):3410-8.

10.

HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.

Yin R, Zheng W, Hao F, Yang XC, Zhong BY, Li QJ.

J Dermatol Sci. 2009 Aug;55(2):116-22. doi: 10.1016/j.jdermsci.2009.04.008. Epub 2009 Jun 4.

PMID:
19500947
11.

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.

Gold JS, Ferrone CR, Guevara-Patiño JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN.

J Immunol. 2003 May 15;170(10):5188-94.

12.

Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.

Matsuo M, Wada H, Honda S, Tawara I, Uenaka A, Kanematsu T, Nakayama E.

J Immunol. 1999 Jun 1;162(11):6420-5.

13.
14.

Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.

Qin Y, Wang XH, Cui HL, Cheung YK, Hu MH, Zhu SG, Xie Y.

Gynecol Oncol. 2005 Feb;96(2):475-83.

PMID:
15661238
15.

Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.

Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG.

Cancer Immunol Immunother. 2008 Nov;57(11):1635-45. doi: 10.1007/s00262-008-0497-2. Epub 2008 Apr 3.

PMID:
18386000
16.

Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.

Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH.

Cancer Res. 2001 Mar 15;61(6):2625-31.

17.

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.

Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A.

Clin Cancer Res. 2004 Apr 15;10(8):2879-90.

18.

Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.

Broder H, Anderson A, Odesa SK, Kremen TJ, Liau LM.

Neurosurg Focus. 2000 Dec 15;9(6):e6.

PMID:
16817689
19.
20.

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.

van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ.

J Immunol. 2004 Dec 1;173(11):6753-9.

Supplemental Content

Support Center